Deep Learning Based Communication: an Adversarial Approach

3rd Doctoral Congress in Engineering will be held at FEUP on the 27th to 28th of June, 2019Deep learning based communication using autoencoder have revolutionized the design of physical layer in wireless communication. In this paper, we propose an adversarial autoencoder to mitigate vulnerability of autoencoder against adversarial attacks. Results confirm the effectiveness of adversarial training by reducing block error rate(BLER) from 90 percent to 56 percent.info:eu-repo/semantics/publishedVersio

220502

Energy-harvesting-powered sensors are increasingly deployed beyond the reach of terrestrial gateways, where there is often no persistent power supply. Making use of the internet of drones (IoD) for data aggregation in such environments is a promising paradigm to enhance network scalability and connectivity. The flexibility of IoD and favorable line-of-sight connections between the drones and ground nodes are exploited to improve data reception at the drones. In this article, we discuss the challenges of online flight control of IoD, where data-driven neural networks can be tailored to design the trajectories and patrol speeds of the drones and their communication schedules, preventing buffer overflows at the ground nodes. In a small-scale IoD, a multi-agent deep reinforcement learning can be developed with long short-term memory to train the continuous flight control of IoD and data aggregation scheduling, where a joint action is generated for IoD via sharing the flight control decisions among the drones. In a large-scale IoD, sharing the flight control decisions in real-time can result in communication overheads and interference. In this case, deep reinforcement learning can be trained with the second-hand visiting experiences, where the drones learn the actions of each other based on historical scheduling records maintained at the ground nodes.This work was supported in part by the National Funds through FCT/MCTES (Portuguese Foundation for Science and Technology), within the CISTER Research Unit under Grant UIDP/UIDB/04234/2020, and in part by the National Funds through FCT, under CMU Portugal Partnership under Project CMU/TIC/0022/2019 (CRUAV).info:eu-repo/semantics/publishedVersio

MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer

[Background] MSR1 repeats are a 36–38 bp minisatellite element that have recently been implicated in the regulation of gene expression, through copy number variation (CNV).[Patients and methods] Bioinformatic and experimental methods were used to assess the distribution of MSR1 across the genome, evaluate the regulatory potential of such elements and explore the role of MSR1 elements in cancer, particularly non-familial breast cancer and prostate cancer.[Results] MSR1s are predominately located at chromosome 19 and are functionally enriched in regulatory regions of the genome, particularly regions implicated in short-range regulatory activities (H3K27ac, H3K4me1 and H3K4me3). MSR1-regulated genes were found to have specific molecular roles, such as serine-protease activity (P = 4.80 × 10−7) and ion channel activity (P = 2.7 × 10−4). The kallikrein locus was found to contain a large number of MSR1 clusters, and at least six of these showed CNV. An MSR1 cluster was identified within KLK14, with 9 and 11 copies being normal variants. A significant association with the 9-copy allele and non-familial breast cancer was found in two independent populations (P = 0.004; P = 0.03). In the white British population, the minor allele conferred an increased risk of 1.21–3.51 times for all non-familial disease, or 1.7–5.3 times in early-onset disease. The 9-copy allele was also found to be associated with increased risk of prostate cancer in an independent population (odds ratio = 1.27–1.56; P =0.009).[Conclusions] MSR1 repeats act as molecular switches that modulate gene expression. It is likely that CNV of MSR1 will affect risk of development of various forms of cancer, including that of breast and prostate. The MSR1 cluster at KLK14 represents the strongest risk factor identified to date in non-familial breast cancer and a significant risk factor for prostate cancer. Analysis of MSR1 genotype will allow development of precise stratification of disease risk and provide a novel target for therapeutic agents.Prostate cancer study is supported by an National Health and Medical Research Council (NHMRC) grant and Career Development Fellowship APP1090505 to JB. The Australian Prostate Cancer BioResource is supported by the NHMRC Enabling Grant APP614296 and by a grant from the Prostate Cancer Foundation, Australia.Peer reviewe

Attitude and Belief of Healthcare Professionals Towards Effective Obesity Care and Perception of Barriers : An Updated Systematic Review and Meta-analysis

Funding Information: This work was supported by the Iran University of Medical Sciences.Peer reviewedPublisher PD

Predictions for the future of kallikrein-related peptidases in molecular diagnostics

Kallikrein-related peptidases (KLKs) form a cancer-related ensemble of serine proteases. This multigene family hosts the most widely used cancer biomarker that is PSA-KLK3, with millions of tests performed annually worldwide. The present report provides an overview of the biomarker potential of the extended KLK family (KLK1-KLK15) in various disease settings and envisages approaches that could lead to additional KLK-driven applications in future molecular diagnostics. Particular focus is given on the inclusion of KLKs into multifaceted cancer biomarker panels that provide enhanced diagnostic, prognostic and/or predictive accuracy in several human malignancies. Such panels have been described so far for prostate, ovarian, lung and colorectal cancers. The role of KLKs as biomarkers in non-malignant disease settings, such as Alzheimer’s disease and multiple sclerosis, is also commented upon. Predictions are given on the challenges and future directions regarding clinically oriented KLK research

The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019

BACKGROUND: Communicable disease control has long been a focus of global health policy. There have been substantial reductions in the burden and mortality of communicable diseases among children younger than 5 years, but we know less about this burden in older children and adolescents, and it is unclear whether current programmes and policies remain aligned with targets for intervention. This knowledge is especially important for policy and programmes in the context of the COVID-19 pandemic. We aimed to use the Global Burden of Disease (GBD) Study 2019 to systematically characterise the burden of communicable diseases across childhood and adolescence. METHODS: In this systematic analysis of the GBD study from 1990 to 2019, all communicable diseases and their manifestations as modelled within GBD 2019 were included, categorised as 16 subgroups of common diseases or presentations. Data were reported for absolute count, prevalence, and incidence across measures of cause-specific mortality (deaths and years of life lost), disability (years lived with disability [YLDs]), and disease burden (disability-adjusted life-years [DALYs]) for children and adolescents aged 0-24 years. Data were reported across the Socio-demographic Index (SDI) and across time (1990-2019), and for 204 countries and territories. For HIV, we reported the mortality-to-incidence ratio (MIR) as a measure of health system performance. FINDINGS: In 2019, there were 3·0 million deaths and 30·0 million years of healthy life lost to disability (as measured by YLDs), corresponding to 288·4 million DALYs from communicable diseases among children and adolescents globally (57·3% of total communicable disease burden across all ages). Over time, there has been a shift in communicable disease burden from young children to older children and adolescents (largely driven by the considerable reductions in children younger than 5 years and slower progress elsewhere), although children younger than 5 years still accounted for most of the communicable disease burden in 2019. Disease burden and mortality were predominantly in low-SDI settings, with high and high-middle SDI settings also having an appreciable burden of communicable disease morbidity (4·0 million YLDs in 2019 alone). Three cause groups (enteric infections, lower-respiratory-tract infections, and malaria) accounted for 59·8% of the global communicable disease burden in children and adolescents, with tuberculosis and HIV both emerging as important causes during adolescence. HIV was the only cause for which disease burden increased over time, particularly in children and adolescents older than 5 years, and especially in females. Excess MIRs for HIV were observed for males aged 15-19 years in low-SDI settings. INTERPRETATION: Our analysis supports continued policy focus on enteric infections and lower-respiratory-tract infections, with orientation to children younger than 5 years in settings of low socioeconomic development. However, efforts should also be targeted to other conditions, particularly HIV, given its increased burden in older children and adolescents. Older children and adolescents also experience a large burden of communicable disease, further highlighting the need for efforts to extend beyond the first 5 years of life. Our analysis also identified substantial morbidity caused by communicable diseases affecting child and adolescent health across the world. FUNDING: The Australian National Health and Medical Research Council Centre for Research Excellence for Driving Investment in Global Adolescent Health and the Bill & Melinda Gates Foundation